Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours

Technologies that can safely edit genes in the brains of adult animals may revolutionize the treatment of neurological diseases and the understanding of brain function. Here, we demonstrate that intracranial injection of CRISPR–Gold, a nonviral delivery vehicle for the CRISPR–Cas9 ribonucleoprotein, can edit genes in the brains of adult mice in multiple mouse models. CRISPR–Gold can deliver both Cas9 and Cpf1 ribonucleoproteins, and can edit all of the major cell types in the brain, including neurons, astrocytes and microglia, with undetectable levels of toxicity at the doses used. We also show that CRISPR–Gold designed to target the metabotropic glutamate receptor 5 (mGluR5) gene can efficiently reduce local mGluR5 levels in the striatum after an intracranial injection. The effect can also rescue mice from the exaggerated repetitive behaviours caused by fragile X syndrome, a common single-gene form of autism spectrum disorders. CRISPR–Gold may significantly accelerate the development of brain-targeted therapeutics and enable the rapid development of focal brain-knockout animal models.Gene editing of a single gene in the brain of an adult mouse model of fragile X syndrome, achieved via the intracranial injection of a nonviral Cas9 delivery vehicle, rescues mice from the exaggerated repetitive behaviours caused by the disease.

[1]  F. Dal-Pizzol,et al.  Effect of acute and long-term administration of gold nanoparticles on biochemical parameters in rat brain. , 2017, Materials science & engineering. C, Materials for biological applications.

[2]  J. Crawley,et al.  Behavioral Phenotyping Assays for Genetic Mouse Models of Neurodevelopmental, Neurodegenerative, and Psychiatric Disorders. , 2017, Annual review of animal biosciences.

[3]  R. Schwarting,et al.  Repetitive behaviors in the Shank1 knockout mouse model for autism spectrum disorder: Developmental aspects and effects of social context , 2014, Journal of Neuroscience Methods.

[4]  Dan D. Stettler,et al.  Driving Opposing Behaviors with Ensembles of Piriform Neurons , 2011, Cell.

[5]  P. Gee,et al.  Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases , 2015, International journal of molecular sciences.

[6]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[7]  S. Warren,et al.  Reactivation of FMR1 by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome , 2016, PloS one.

[8]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[9]  C. McDougle,et al.  Psychopharmacological Interventions in Autism Spectrum Disorder , 2014, Harvard review of psychiatry.

[10]  Steven Lin,et al.  Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.

[11]  Richard Paylor,et al.  Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic‐like responses , 2011, Autism research : official journal of the International Society for Autism Research.

[12]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[13]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[14]  N. Nishiyama,et al.  Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Y. Jan,et al.  Bidirectional Regulation of Dendritic Voltage-Gated Potassium Channels by the Fragile X Mental Retardation Protein , 2011, Neuron.

[16]  Jacqueline N. Crawley,et al.  Negative Allosteric Modulation of the mGluR5 Receptor Reduces Repetitive Behaviors and Rescues Social Deficits in Mouse Models of Autism , 2012, Science Translational Medicine.

[17]  D. Cleveland,et al.  Gene therapy: Gene-editing therapy for neurological disease , 2017, Nature Reviews Neurology.

[18]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[19]  Qi Ding,et al.  Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background , 2014, Behavioural Brain Research.

[20]  Jill L Silverman,et al.  Modeling fragile X syndrome in the Fmr1 knockout mouse. , 2014, Intractable & rare diseases research.

[21]  R. Paylor,et al.  Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety , 2009, Psychopharmacology.

[22]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[23]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[24]  M. Bear,et al.  Therapeutic implications of the mGluR theory of fragile X mental retardation , 2005, Genes, brain, and behavior.

[25]  M. Bear,et al.  Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome , 2008, The Journal of physiology.

[26]  T. Yamamori,et al.  Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex , 2015, Neuroscience Research.

[27]  Mark R. Servos,et al.  Instantaneous and quantitative functionalization of gold nanoparticles with thiolated DNA using a pH-assisted and surfactant-free route. , 2012, Journal of the American Chemical Society.

[28]  M. Raspa,et al.  Public Health Literature Review of Fragile X Syndrome , 2017, Pediatrics.

[29]  B. Kaang,et al.  Neuronal mechanisms and circuits underlying repetitive behaviors in mouse models of autism spectrum disorder , 2016, Behavioral and Brain Functions.

[30]  T. Möller,et al.  Lentiviral transduction of microglial cells , 2005, Glia.

[31]  Allan R. Jones,et al.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain , 2009, Nature Neuroscience.

[32]  G. Kreiman,et al.  Internally Generated Preactivation of Single Neurons in Human Medial Frontal Cortex Predicts Volition , 2011, Neuron.

[33]  S. Gasser,et al.  Generating Primary Fibroblast Cultures from Mouse Ear and Tail Tissues. , 2016, Journal of visualized experiments : JoVE.

[34]  Y. Hung,et al.  Size-dependent impairment of cognition in mice caused by the injection of gold nanoparticles , 2010, Nanotechnology.

[35]  Akshata A Almad,et al.  Glia: an emerging target for neurological disease therapy , 2012, Stem Cell Research & Therapy.

[36]  Feng Zhang,et al.  In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 , 2014, Nature Biotechnology.

[37]  H. Tozaki-Saitoh,et al.  Lentiviral transduction of cultured microglia. , 2013, Methods in molecular biology.

[38]  V. Napolioni,et al.  Autism genetics , 2013, Behavioural Brain Research.

[39]  H. McFarlane,et al.  Autism‐like behavioral phenotypes in BTBR T+tf/J mice , 2008, Genes, brain, and behavior.

[40]  O. Yanuka,et al.  Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons. , 2015, Cell reports.

[41]  Freeman Lan,et al.  Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair , 2017, Nature Biomedical Engineering.

[42]  K. High,et al.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.

[43]  G. Feng,et al.  Imaging Neuronal Subsets in Transgenic Mice Expressing Multiple Spectral Variants of GFP , 2000, Neuron.

[44]  Anirvan Ghosh,et al.  Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes , 2017, Nature Biotechnology.

[45]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[46]  R. Findling,et al.  Pharmacotherapy for mental health problems in people with intellectual disability , 2016, Current opinion in psychiatry.

[47]  George M. Church,et al.  Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA) , 2014, Bioinform..

[48]  M. Bear,et al.  Negative Allosteric Modulation of mGluR5 Partially Corrects Pathophysiology in a Mouse Model of Rett Syndrome , 2016, The Journal of Neuroscience.

[49]  S. Fukushima,et al.  Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. , 2008, Journal of the American Chemical Society.

[50]  A. Regev,et al.  Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System , 2015, Cell.

[51]  A. Sidhu,et al.  Mice expressing the A53T mutant form of human alpha‐synuclein exhibit hyperactivity and reduced anxiety‐like behavior , 2010, Journal of neuroscience research.

[52]  M. Bear,et al.  Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome , 2010, The Journal of Neuroscience.

[53]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[54]  Brenda J Butka.  Imaging , 2003, JAMA.

[55]  N. Maitland,et al.  Macrophages in gene therapy: cellular delivery vehicles and in vivo targets , 2002, Journal of leukocyte biology.